Skip to main content

Phenylbutazone Disease Interactions

There are 2 disease interactions with phenylbutazone.

Major

NSAIDs (applies to phenylbutazone) GI toxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Intestinal Anastomoses

Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can develop at any time, with or without warning symptoms. NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as: prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy. Particular vigilance is necessary when treating older adult or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.

References (17)
  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
  2. (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
  3. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  4. (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
  5. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  6. (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
  7. (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
  8. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  9. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  10. (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
  11. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  12. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  13. (2001) "Product Information. Daypro (oxaprozin)." Searle
  14. (2001) "Product Information. Celebrex (celecoxib)." Searle
  15. (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
  16. (2022) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals Group, SUPPL-52
  17. (2025) "Product Information. Symbravo (meloxicam-rizatriptan)." Axsome Therapeutics, Inc.
Moderate

NSAIDs (applies to phenylbutazone) hyperkalemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Caution is advised in patients with hyperkalemia.

References (17)
  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
  2. (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
  3. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  4. (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
  5. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  6. (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
  7. (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
  8. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  9. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  10. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  11. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Daypro (oxaprozin)." Searle
  13. (2001) "Product Information. Celebrex (celecoxib)." Searle
  14. (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
  15. (2006) "Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group
  16. (2022) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals Group, SUPPL-52
  17. (2025) "Product Information. Symbravo (meloxicam-rizatriptan)." Axsome Therapeutics, Inc.

Switch to consumer interaction data

Phenylbutazone drug interactions

There are 611 drug interactions with phenylbutazone.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.